Outcomes after UMRD with 1st line Ib +Ven Fixed Duration Treatment Versus Continued Ibr Follow-up in the CAPTIVATE Study

[Jm954]

First-line Ibr + Ven is an all-oral, once-daily, chemotherapy-free regimen that continues to provide deep, durable clinical responses in pts with CLL.

With additional follow-up in pts with confirmed uMRD after Ibr + Ven, 4-y OS rates were ≥98% and 4-y PFS rates were ≥88% in pts randomly assigned to fixed duration or continued Ibrutinib.

The durability of uMRD and the 3-y disease free survival rate of 85% without ongoing treatment are encouraging and support the promising potential for treatment-free remission.

Together with the safety data, these results demonstrate a favorable benefit-risk profile with fixed duration Ibr + Ven.

More here: ash.confex.com/ash/2022/web...

Jackie

[Newdawn Administrator]

I’m liking this! 😊

Newdawn

[Mystic75]

Thank you, Jackie! Very timely post. As I've posted previously, my husband was on the CAPTIVATE fixed cohort trial, having his last treatment April 30, 2019. (Can't believe it's already been 4 years!)

Monday he had a CT Scan and tomorrow he meets with the doctor, which is part of his routine followup, to review the results.

I'll post after we've met with the doctor. Fingers crossed!!

D.

[Jmiah717 in reply to Mystic75]

Still in remission and progression free?

[Mystic75 in reply to Jmiah717]

As far as we know. We'll know more later today once we hear the results back from the CT Scan.

Nothing as of yet indicates he has relapsed. Can't go by how he feels since my husband claimed he felt fine up to the time he had treatment, and at that time his bone marrow was 70% impacted and his spleen was 23 cm. Never affected his appetite, either.

D.

[studebaker in reply to Mystic75]

🤞🏻🤞🏻🤞🏻🤞🏻🤞🏻

[Mystic75 in reply to studebaker]

Thank you! We're in the waiting room now.